Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Tablets: SOP for Handling Non-Conforming Products During Manufacturing – V 2.0

Posted on By

Tablets: SOP for Handling Non-Conforming Products During Manufacturing – V 2.0

Standard Operating Procedure for Handling Non-Conforming Products During Manufacturing

Department Tablet
SOP No. SOP/TAB/218/2025
Supersedes SOP/TAB/218/2022
Page No. Page 1 of 5
Issue Date 01/03/2026
Effective Date 06/03/2026
Review Date 01/03/2027

1. Purpose

This SOP defines the procedures for identifying, handling, and resolving non-conforming products during the tablet manufacturing process. Its goal is to ensure that non-conforming products are properly managed to prevent their distribution and to improve overall product quality.

2. Scope

This SOP applies to all non-conforming products detected during tablet manufacturing, including raw materials, intermediates, and finished tablets. It covers all activities from identification, segregation, investigation, corrective actions, and documentation.

3. Responsibilities

  • Production Manager: Responsible for identifying non-conforming products, ensuring their proper segregation, and reporting them to the Quality Assurance (QA) team.
  • Quality Control (QC) Team: Responsible for evaluating the non-conforming products, conducting investigations, and providing recommendations for corrective actions.
  • Quality Assurance (QA) Manager: Responsible for overseeing the resolution of non-conformances, reviewing investigation reports, and ensuring compliance with regulatory requirements.
  • Regulatory Affairs Team: Ensures that non-conforming products are handled according to regulatory guidelines, especially when deviations could affect product compliance or safety.

4. Accountability

The QA Manager is accountable

for ensuring that the non-conforming products are properly handled, investigated, and resolved according to this SOP. The Production Manager and QC Team are responsible for identifying, segregating, and reporting non-conformances.

See also  Tablets: SOP for Wet Granulation Equipment Setup and Operation - V 2.0

5. Procedure

5.1 Identification and Segregation of Non-Conforming Products

  1. Identify non-conforming products through in-process inspections, QC testing, or visual examination during manufacturing (e.g., tablets failing hardness or disintegration testing).
  2. Immediately segregate non-conforming products from conforming products to prevent cross-contamination or accidental release.
  3. Label the non-conforming products clearly with a “Non-Conforming Product” label and place them in a designated quarantine area.
  4. Document the details of the non-conformance, including the batch number, product name, and nature of the non-conformance (Annexure-1).

5.2 Investigation of Non-Conformance

  1. The QC Team investigates the root cause of the non-conformance by reviewing batch records, conducting product testing, and analyzing the manufacturing process (Annexure-2).
  2. Use appropriate investigative techniques such as Root Cause Analysis (RCA) to identify the underlying cause of the non-conformance (Annexure-3).
  3. Document all findings from the investigation, including potential causes, impacts, and corrective action recommendations (Annexure-4).

5.3 Corrective Actions

  1. Develop corrective actions based on the investigation findings to address the root cause and prevent recurrence of the non-conformance (Annexure-5).
  2. Implement corrective actions as soon as possible and document all actions taken (Annexure-6).
  3. Verify the effectiveness of corrective actions by conducting follow-up inspections and testing of products produced after implementation (Annexure-7).
See also  Tablets: SOP for Screening and Milling of Granules for Tablets - V 2.0

5.4 Reprocessing or Disposition of Non-Conforming Products

  1. If a non-conforming product can be reprocessed or reworked to meet quality specifications, provide detailed instructions on the steps to follow (e.g., re-blending, re-compressing, or re-coating) (Annexure-8).
  2. If the non-conforming product cannot be reprocessed or reworked, it must be properly disposed of according to the company’s waste disposal procedures (Annexure-9).
  3. Ensure that all reprocessed or disposed products are documented appropriately, with proper tracking and accountability (Annexure-10).

5.5 Documentation and Record Keeping

  1. Ensure that all records related to non-conforming products, investigations, corrective actions, and reprocessing or disposal are documented and securely stored (Annexure-11).
  2. Retain all records for a minimum of 5 years or as required by applicable regulations.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • QC: Quality Control
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Non-Conformance Report (Annexure-1)
  2. Investigation Report (Annexure-2)
  3. Root Cause Analysis Report (Annexure-3)
  4. Corrective Action Plan (Annexure-4)
  5. Corrective Action Implementation Record (Annexure-5)
  6. Reprocessing Instructions (Annexure-6)
  7. Disposal Records (Annexure-7)
  8. Reprocessing and Disposal Documentation (Annexure-8)
  9. Non-Conformance Documentation (Annexure-9)

8. References

  • 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals (US FDA)
  • ISO 9001 – Quality Management Systems
  • GMP Guidelines for Pharmaceutical Manufacturing

9. SOP Version

Version: 2.0

See also  Tablets: SOP for Monitoring Drying Time in Sugar-Coating Process - V 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Non-Conformance Report

Non-Conformance ID Description Batch Number Action Taken
NC001 Potency Out of Specification Batch123 Recalibrated equipment and retested

Annexure-2: Investigation Report

Investigation ID Findings Corrective Action
INV001 Improper calibration of equipment Recalibrate equipment and perform routine checks

Annexure-3: Root Cause Analysis Report

Cause ID Root Cause Description Corrective Action
RCA001 Inconsistent calibration of tablet hardness tester Establish routine calibration schedule

Annexure-4: Corrective Action Plan

Action ID Action Description Completion Date
CAP001 Recalibrate equipment 06/03/2026

Annexure-5: Corrective Action Implementation Record

Action ID Action Implemented By Result
CAP001 Jane Smith Successfully recalibrated equipment

Annexure-6: Reprocessing Instructions

Batch Number Reprocessing Instructions Completion Date
Batch123 Re-blend and compress 06/03/2026

Annexure-7: Disposal Records

Batch Number Disposal Method Disposal Date
Batch123 Incineration 06/03/2026

Annexure-8: Reprocessing and Disposal Documentation

Batch Number Action Taken Completion Date
Batch123 Reprocessing completed 06/03/2026

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP creation New process QA Head
01/02/2025 2.0 Added documentation and tracking requirements Annual review QA Head
Tablet Manufacturing V2.0 Tags:GMP tablet manufacturing SOP, SOP for tablet production, SOP for tablet quality control, SOP tablet inspection process, SOP tablet packing and sealing, Tablet batch record review, Tablet blending SOP, Tablet cleaning and maintenance, Tablet coating procedure, Tablet compression SOP, Tablet disintegration test procedure, Tablet dissolution procedure, Tablet formulation SOP, Tablet friability testing SOP, Tablet labeling and packaging SOP, Tablet manufacturing equipment SOP, Tablet manufacturing SOP, Tablet manufacturing SOPs, Tablet packaging SOP, Tablet production procedure, Tablet quality assurance SOP, Tablet quality control SOP, Tablet sampling and in-process testing SOP, Tablet stability testing SOP, Tablet storage and handling procedure, Tablet uniformity testing procedure, Tablet weight variation SOP

Post navigation

Previous Post: Capsule: SOP for Preparing Batch Manufacturing Records for Capsules – V 2.0
Next Post: API Manufacturing: SOP for Issuance of Raw Materials to Production – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version